- Home
- AVTX vs SLRC Comparison
AVTX vs SLRC Comparison
Compare AVTX & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVTX | SLRC |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 691.2M |
| IPO Year | 2015 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AVTX | SLRC |
|---|---|---|
| Price | $7.48 | $11.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $44.08 | $14.88 |
| AVG Volume (30 Days) | ★ 1.0M | 352.8K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 11.27% |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.90 |
| P/E Ratio | ★ N/A | $23.35 |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $11.21 | $10.96 |
| 52 Week High | $24.27 | $16.36 |
Technical Indicators
Market Signals| Indicator | AVTX | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 18.40 | 39.23 |
| Support Level | N/A | $11.23 |
| Resistance Level | $20.54 | $11.61 |
| Average True Range (ATR) | 0.97 | 0.19 |
| MACD | -0.26 | 0.00 |
| Stochastic Oscillator | 8.65 | 43.18 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.